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pN1 stage, 190 pts with pT1-2 N2 while 100 pts with pT1/2 
pN3 stage. Hystological subtype was luminal A ( lA=Er+/ Pr+ , 
Her neg G1-G2) in 164 pts; luminal B ( lB= Er+/Pr+, Her2 neg 
G3) in 170 pts; triple negative (TN= Er- Pr- Her2 neg) in 166 
pts. Mean age was 65 yrs (range: 40-72 yrs). Patients were 
treated with chemotherapy according to prognostic features. 
All patients received whole breast radiotherapy witha a 
totale dose of 50 Gy + 10 Gy boost and 48-50 Gy on 
supraclavicular fossa. In case of medial tumors, the internal 
mammary chain was included. Kaplan-Meyer and paired t-test 
were used for statistical analysis. 
 
Results: The 5-year LRR and DR were obtained with a median 
of 6.3 years. The 5-year LRR was 1.9% in lA, 2.8 % in l B , 
2.1% in TN ( p= .72). The 5-year DR was in lA 2%, lB 4.5%, 8 % 
in TN (p<.001) According to nodal status LRR was 1.7% in N1, 
2.3% in N2 and 3.8% in N3 status (p= .005). The 5-year DR in 
N1 lA was 2.4 %, for lB was 3%, for TN was 3.5% ( p= .82) 
while in N2 lA it was 3 %,for lB was 5% and for TN it was 7.3% 
(p= .06); for N3 lA was 3.5%, for lB was 4.8%, for TN was 
8.5%; overall DR of pN1 versus pN2/N3 was statistically 
significant (p= .02). On multivariate analyses high risk of LRR 
was related to T size (T>2 cm), presence of lymphovascular 
invasion, lobular hystology; high risk of DR was observed for 
N> 4 nodes, presence of ECE, Ki 67> 30% and age <50 years. 
 
Conclusion: : In this analysis triple negative breast cancer 
patients with pN1 seem to benefit by nodal radiation, but 
further studies are necessary 
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Purpose or Objective: To analyze outcome with adjuvant 
treatment in male breast cancer (MBC) patients. 
 
Material and Methods: From 1991 to 2013, 68 men with 
breast cancer were retrospectively analyzed for 
demographic, clinico-pathological and treatment outcomes. 
Disease-free survival (DFS) was defined as time duration from 
diagnosis to first recurrence. Overall survival (OS) was 
defined as time duration from pathologic diagnosis to death 
or last follow-up with any death defined as an event. DFS and 
OS were estimated using Kaplan-Meier method and compared 
between patients receiving and not receiving adjuvant 
treatment using log-rank test.  
 
Results: Mean age was 55 years (range 30-76). Right, left and 
bilateral BC was seen in 37(54%), 30(44%) and 1(1%) men 
respectively. Mean duration of symptoms was 25 months 
(range 1-240). Comorbidity was present in 22(36%) patients. 
Family history was present in 3(4%) patients. Mean tumor size 
was 5x5cm (range 1x1-10x10cm). Nipple was involved in 
24(35%) men. Early, locally advanced and metastatic disease 
was seen in 27(39%), 29(43%) and 13(19%) patients 
respectively. Majority 51(84%) had IDC histology. In radically 
treated 56 men, NACT with FAC regimen was given to 10(18%) 
patients; with CR in 4(40%) and PR in 6(60%) patients. 
Mastectomy was done in 48(86%) and WLE in 8(14%) men. 
Margins and nodes were positive in 13(23%) and 30(54%) men 
respectively. ER, PR and Her2neu positive were 22(39%), 
12(22%) and 2(3.5%) patients respectively. Adjuvant 
radiotherapy, chemotherapy and tamoxifen was received by 
45(80%), 25(45%) and 37(66%) men respectively. Median 
follow up was 52 months (range 1-278). Local recurrence 
occurred in 8(14.5%) and distant metastasis in 18(33%) men 
respectively. DFS and OS at 10 year was 41% and 49% 
respectively. DFS and OS was significantly better in men with 
adjuvant radiation (53% vs 12%, p=0.002 and 57% vs 22%, 
p=0.005 respectively) and hormonal therapy (58% vs 14%, 
p=0.004 and 58% vs 39%, p=0.036). Chemotherapy had no 
impact on DFS and OS. 
 
Conclusion: Adjuvant radiotherapy and hormonal therapy 
significantly improve DFS and OS in male patients with breast 
cancer. Chemotherapy had no impact on DFS and OS. 
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Purpose or Objective: The intraoperative boost radiotherapy 
is a validated method to irradiate the tumor bed immediately 
after surgery with an effective dose. The most 
homogeneously dose can be achieved with electrons 
(intraoperative radiotherapy with electrons = IOERT). 
Because of the high individual dose are chronic side effects 
of particular interest. Therefore we investigated the late side 
effects with a median of 31 months (5-54 months). 
 
Material and Methods: From 10/2010 until 12/2013 n=138 
patients received IOERT (NOVAC 7, New Radiant Technology, 
Aprilia, Italy) with 1x10 Gy covering the 90% isodose followed 
by whole-breast radiotherapy with 50.4 Gy/1.8 Gy SD. 58 
patients were re-evaluated regarding late side effects and 
cosmetic outcome until 10/2015. The energy was determined 
by measuring the distance from the surface tot he rib by 
intraoperative ultrasound. We investigated the radiogenic 
side effects according to the LENT-SOMA criteria. 
Furthermore, we evaluated the cosmetic results (subjective / 
objective). 
 
Results: Pain in the irradiated breast was denied by 81% of 
all patients. Pain grade 1 was reported by 15.5% and grade 2 
by 3.4% of the patients. There was no breast edema 
detectable in 91.4%. We found an edema grade 1 in 5.2% and 
grade 2 in 3.4% oft he patients. There was no significant 
correlation between edema and pain (p = 0.326). A lymph 
edema grade 1 in the arm occurred in 5.2%. A retraction of 
the scar was not recorded for 91.4%, a retraction grade1 in 
6.9% and a retraction grade 2 in 1.7%. None of the patients 
developed a radiogenic ulcer. Fibrosis was not recorded in 
75.9%, a fibrosis grade 1 in 20.7%, a fibrosis grade 2 in 3.4% 
.Telangiectasia’s have not occurred in 96.6%. No visible 
hyperpigmentation was found for 70.7%, and 29.3% had a 
grade 1 hyperpigmentation 1. One patient showed 
inhomogenities in the heart MRT, which was performed to 
rule out heart disease. One patient developed pneumonitis. 
The cosmetic results (patient's view) was very good in 41.4%, 
good in 41.4%, moderate in 10.3% and bad in 3.4%. The 
assessment of the physician (physician`S view) was in 48.3% 
very good, good in 34.5%, moderate 6.9% and bad in 1.7%. 
Moderate or bad results mostly occured in patients with small 
breasts and large tumor size. 
 
Conclusion: IOERT followed by whole-breast radiotherapy by 
50.4Gy/1.8 Gy SD is associated with a low incidence of late 
side effects. The cosmetic outcome is after objective and 
subjective assessment in the majority (82.8%) of patients 
very good or good. 
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Purpose or Objective: Acute skin toxicity is a frequent side 
effect of breast irradiation affecting quality of life of breast 
cancer patients. Ameliorating these unwished events may 
have a positive impact on the therapeutic course of the 
patients. In this study we tested a thymine-lysine-hyaluronic 
